19/08/2019 - AB Science announces the success of a private placement
22/07/2019 - AB Science Corporate Presentation - July 2019
AB Science Corporate Presentation
12/08/2019 - AB science will present a corporate overview at two upcoming healthcare conferences in September 2019, in New York.
07/11/2019 - AScience announces that AB8939 receives Orphan Drug Designation for Acute Myeloid Leukemia from FDA
21/03/2019 - AB Science announces acceptance of abstract for oral presentation at the 2019 Muscular Dystrophy Association Conference.
30/04/2019 - AB Science reports its annual financial results as of 31 December 2018.
24/10/2019 - AB Science granted authorization to initiate phase 3 confirmatory study of masitinib in indolent systemic mastocytosis
22/11/2019 - AB Science provides clarification regarding the article in the newspaper Les Echos related to the investigation by the French market
06/11/2019 - AB Science has signed a financing agreement in order to pre-finance the 2019 research tax credit
30/09/2019 - AB Science reports its revenues for the first half of 2019
06/11/2019 - AB Science announces the first presentation of preclinical results of compound AB8939 in the 61st ASH Annual meeting online
08/07/2019 - AB Science web conference presentation
14/06/2019 - AB Science web conference presentation
04/06/2019 - AB Science web conference presentation (Part 1)
05/06/2019 - AB Science web conference - Part 2
28/05/2019 - AB Science announces the lifting of the ANSM clinical hold.
12/06/2019 - AB Science announces the positive recommendation of IDMC following the interim analysis of AB12005 study in the first-line treatment
07/11/2019 - AB Science announces positive top-line phase 3 results for oral masitinib in severe asthma
16/04/2019- AB Science presented new preclinical data for masitinib in ALS at the 2019 Muscular Dystrophy Association Conference.
Page 1 of 2